A phase 3 randomized, open-label, multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Disease Types: Lung - Non-Small Cell Lung, STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Chicago Resurrection, Niles

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202) (20190341)

Disease Types: Lung - Non-Small Cell Lung

Available at: Arlington Heights, Niles

An open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer (TIGOS-LS) (CA245-0004)

Disease Types: Lung - Small Cell Lung

Available at: Arlington Heights, Chicago Resurrection, Niles

A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC), D798EC00001

Disease Types: Head/Neck

Available at: Arlington Heights, Niles

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Disease Types: Breast

Available at: Arlington Heights, Chicago Resurrection, Niles

DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (D781PC00001)

Disease Types: Colorectal/GI/Gastrointestinal

Available at: Arlington Heights, Chicago Resurrection, Niles

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Disease Types: Solid Tumor, STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Chicago Resurrection, Niles

TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Disease Types: Cholangiocarcinoma, STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Niles, Chicago Resurrection

Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours (1479-0009)

Disease Types: Solid Tumor

Available at: Arlington Heights, Niles

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Disease Types: Solid Tumor, STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Niles

TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Disease Types: Cholangiocarcinoma, STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Niles

A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Disease Types: Head/Neck, STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Niles

A Phase I−III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with Locally Advanced, Unresectable, Stage III Non−Small Cell Lung Cancer

Disease Types: Lung - Non-Small Cell Lung, STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Niles

A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Disease Types: Lung - Non-Small Cell Lung

Available at: Arlington Heights, Niles

A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (SGN-B6A-002)

Disease Types: Lung - Non-Small Cell Lung

Available at: Arlington Heights, Niles

A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Disease Types: Lung - Small Cell Lung

Available at: Arlington Heights, Niles

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Disease Types: Lung - Non-Small Cell Lung

Available at: Arlington Heights, Niles

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Disease Types: Lung - Non-Small Cell Lung

Available at: Arlington Heights, Niles

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)

Disease Types: Lung - Non-Small Cell Lung

Available at: Arlington Heights, Niles

A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Disease Types: Endometrial

Available at: Arlington Heights

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Disease Types: Breast

Available at: Arlington Heights, Niles

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation. (849-007) (Mirati Therapeutics)

Disease Types: Lung - Non-Small Cell Lung

Available at: Arlington Heights, Niles

A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma (EZH-302)

Disease Types: Lymphoma

Available at: Arlington Heights, Niles

A Phase 1/2, Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Disease Types: Solid Tumor

Available at: Niles